Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities

Our plain-English summary of Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities, by T. Zahiu, C.M. Mihu, B.A. Bosca, et al (Diagnostics, 2025).

The study

• Authors: T. Zahiu, C.M. Mihu, B.A. Bosca, M. Mărginean, L.P. Mocan, R.A. Ștefan, R.T. Suflețel, C. Mihu, C.S. Melincovici
• Journal: Diagnostics
• Published: 2025;15(11)
• Type of article: Review
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Pleural mesothelioma (PM) is a rare disease, which is going to be a global medical concern in the 21st century, because of its aggressiveness, late diagnosis, and insufficient therapies. This review seeks to enhance the comprehension of medical professionals regarding the risk factors and environmental influences that contribute to the development of the disease, as well as its underlying mechanisms. In addition, we aim to provide a schematic yet thorough overview of diagnostic techniques in PM, emphasizing the significance of the immunohistochemical markers BAP1 and MTAP, with the latter serving as an almost ideal surrogate for the gold-standard diagnostic approach, FISH p16/CDKN2A deletion. The scientific world is grappling with BAP1, MTAP, and the tumour inflammatory microenvironment, because they are the key for personalized treatments and palliative care in this disease. Considering that the survival rate for patients with PM seldom surpasses five years, every moment is significant. Therefore, our article also highlights recent advancements in clinical assessments related to prognostic scoring and treatment options. PM is a complex disease, with gradual progression over decades, which requires further investigation covering the prevention, mutations, diagnosis and treatment.

In plain English

This article was a narrative review of published research on pleural mesothelioma, a cancer of the lining around the lungs that the authors described as mainly caused by asbestos exposure. It reported no new patient data. The review covered epidemiology, risk factors (asbestos and other fibres such as erionite), how the disease develops, diagnostic methods, the inflammatory surroundings of the tumour, prognosis, and treatments under study. It focused on two tissue-staining (immunohistochemistry) markers, BAP1 and MTAP. Citing earlier studies, the authors reported that loss of BAP1 staining had 100% specificity, with sensitivity of 66% to 76% in tissue (histological) samples and 60% to 68% in cell (cytological) samples. They reported that negative MTAP staining also had 100% specificity but lower sensitivity. They described studies on whether BAP1 predicts survival as controversial. Summarising treatment trials, they wrote that none of the therapies showed exceptional efficacy. They added that a meta-analysis could not be done because the studies varied too much. The authors concluded that using immunohistochemistry for these markers is likely to improve the quality-to-cost ratio of diagnosis.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published literature (no new data collected)
• Who was studied: No study population of its own; the authors reviewed published studies on pleural mesothelioma covering epidemiology, risk factors, mechanisms, diagnosis, molecular features and therapies
• Exposure: Asbestos in general, described as the main cause of mesothelioma; the review also mentions other fibres (erionite, zeolite, ophiolite, fluoro-edenite) as causes in some areas
• Main results:
  • From cited studies: immunohistochemistry detects BAP1 loss with 100% specificity; sensitivity was 66% to 76% in histological samples and 60% to 68% in cytological samples
  • From cited studies: BAP1 sensitivity figures by sample type
  • From cited studies: negative MTAP staining had 100% specificity, with sensitivity of 38 to 44% in cytological samples and 42 to 55% in histological samples
  • From a cited source: FISH testing for p16/CDKN2A loss showed 100% specificity, with sensitivity for pleural mesothelioma ranging from 48% to 88%
  • The authors described studies on the prognostic value of BAP1 as controversial
  • In the authors' summary of treatment studies, no therapy showed exceptional efficacy, and results varied by conditions
• The authors' conclusion: The authors concluded that using immunohistochemistry to assess BAP1 and MTAP is likely to improve the quality-to-cost ratio of diagnosis, and that a deeper understanding of the genes and markers involved is needed
• Limitations the authors state:
  • The authors stated that a meta-analysis of the treatment studies could not be done because study conditions and methods varied too much

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, BAP1, MTAP, Fluorescence In Situ Hybridization (FISH), CDKN2A, Palliative Care.

Related studies

• Effects of Chrysotile Exposure in Human Bronchial Epithelial Cells: Insights into the Pathogenic Mechanisms of Asbestos-Related Diseases — G.R. Gulino, M. Polimeni, et al. (2016)
• New insight into the molecular mechanisms of the biological effects of DNA minor groove binders — X. Zhang, S.C. Zhang, et al. (2011)
• Insights into the molecular mechanisms underlying the function of lysyl oxidase like 1 in cancers — X. Wang, X. Wang, et al. (2025)
• New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas — B.T. Mossman, A. Shukla, et al. (2013)
• New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma — T. Patel (2014)
• Establishment and characterization of CRISPR/Cas9-mediated NF2-/- human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma — M. Wahiduzzaman, S. Karnan, et al. (2019)

Browse more research in Diagnostics, or return to medical research.